Jamil Ahmed, MD
Physical Medicine & Rehabilitation · Fresno, CANPI 1043242670
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AstraZeneca accounts for 79.1% of it on its own, with 2 other manufacturers making up the rest. 2023 is the largest year on record at $110, 6.4 times the $17 reported in 2019. That places this record below the midpoint for physical medicine & rehabilitation clinicians in CA, where the typical reported total is $142.
Across 3 payments — averaging $46.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$110
- Pfizer$17
- Biodelivery Sciences International, Inc.$12
What the payments were for
- Food & beverage$139100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $110 |
| Pfizer | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$110
How this compares
$139 in reported general payments places this provider in the 45th percentile of 830 physical medicine & rehabilitation providers in California.
See all physical medicine & rehabilitation providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 688 | $16,462 |
| Naloxone Hcl | 39 | $2,502 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 38 | $1,502 |
| Morphine Sulfate | 51 | $1,028 |
| Gabapentin | 79 | $919 |
| Baclofen | 75 | $679 |
| Oxycodone Hcl | 39 | $436 |
| Cyclobenzaprine Hcl | 50 | $415 |
| Tizanidine Hcl | 98 | $377 |
| Tramadol Hcl | 48 | $179 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Fresno
- Ziyad AyyoubParamount$322K
- Pratik GandhiAnaheim$122K
- Mary OatesSanta Maria$115K
- Kevin BarretteSan Francisco$84K
- Steven SampsonLos Angeles$63K
- Jeffrey ChenSan Diego$59K
- Nanette JoyceSacramento$56K
- Amir RahnavardMonterey$49K
- Kyle RyanSan Diego$39K
- Kyle YangLos Angeles$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.